<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36211670</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2296-2565</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in public health</Title><ISOAbbreviation>Front Public Health</ISOAbbreviation></Journal><ArticleTitle>Cost-effectiveness of various immunization schedules with inactivated Sabin strain polio vaccine in Hangzhou, China.</ArticleTitle><Pagination><StartPage>990042</StartPage><MedlinePgn>990042</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">990042</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fpubh.2022.990042</ELocationID><Abstract><AbstractText Label="BACKGROUND">It is necessary to select suitable inactivated poliovirus vaccine(IPV) and live, attenuated oral poliovirus vaccine (OPV) sequential immunization programs and configure the corresponding health resources. An economic evaluation was conducted on the sequential procedures of Sabin strain-based IPV (sIPV) and bivalent OPV (bOPV) with different doses to verify whether a cost-effectiveness target can be achieved. This study aimed to evaluate the cost-effectiveness of different sIPV immunization schedules, which would provide convincing evidence to further change the poliovirus vaccine (PV) immunization strategies in China.</AbstractText><AbstractText Label="METHODS">Five strategies were included in this analysis. Based on Strategy 0(S<sub>0</sub>), the incremental cost (IC), incremental effect (IE), and incremental cost-effectiveness ratio (ICER) of the four different strategies (S<sub>1</sub>/S<sub>2</sub>/S<sub>3</sub>/S<sub>4</sub>) were calculated based on the perspective of the society. Seven cost items were included in this study. Results of field investigations and expert consultations were used to calculate these costs.</AbstractText><AbstractText Label="RESULTS">The ICs of S<sub>1</sub>/S<sub>2</sub>/S<sub>3</sub>/S<sub>4</sub> was Chinese Yuan (CNY) 30.77, 68.58, 103.82, and 219.82 million, respectively. The IE of vaccine-associated paralytic poliomyelitis (IE<sub>VAPP</sub>) cases of S<sub>1</sub>/S<sub>2</sub>/S<sub>3</sub>/S<sub>4</sub> were 0.22, 0.22, 0.22, and 0.11, respectively, while the IE of disability-adjusted life-years (IE<sub>DALY</sub>) of S<sub>1</sub>/S<sub>2</sub>/S<sub>3</sub>/S<sub>4</sub> were 8.98, 8.98, 8.98, and 4.49, respectively. The ICER<sub>VAPP</sub> of S<sub>1</sub>/S<sub>2</sub>/S<sub>3</sub>/S<sub>4</sub> gradually increased to CNY 13.99, 31.17, 47.19, and 199.83 million/VAPP, respectively. The ICER<sub>DALY</sub> of S<sub>1</sub>/S<sub>2</sub>/S<sub>3</sub>/S<sub>4</sub> also gradually increased to CNY 0.34, 0.76, 1.16, and 4.90 million/DALY, respectively.</AbstractText><AbstractText Label="CONCLUSION">ICER<sub>VAPP</sub> and ICER<sub>DALY</sub> were substantially higher for S<sub>3</sub> (four-sIPV) and S<sub>4</sub> (replacement of self-funded sIPV based on one-sIPV-three-bOPV). Two-sIPV-two-bOPV had a cost-effectiveness advantage, whereas S2/S3/S4 had no cost-effectiveness advantage.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Xu, Liu, Wang, Che, Du, Zhang, Gu, Zhang and Jiang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Yuyang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Che</LastName><ForeName>Xinren</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiaoping</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Wenwen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xuechao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Public Health</MedlineTA><NlmUniqueID>101616579</NlmUniqueID><ISSNLinking>2296-2565</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IPV</Keyword><Keyword MajorTopicYN="N">Sabin strain</Keyword><Keyword MajorTopicYN="N">cost-effectiveness</Keyword><Keyword MajorTopicYN="N">dose</Keyword><Keyword MajorTopicYN="N">immunization schedules</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>10</Day><Hour>3</Hour><Minute>59</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36211670</ArticleId><ArticleId IdType="pmc">PMC9545176</ArticleId><ArticleId IdType="doi">10.3389/fpubh.2022.990042</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Liu JH, Tong GM. Progress of poliomyelitis vaccine research. Prog Microbiol Immunol. (2011) 39:72&#x2013;4. 10.3969/j.issn.1005-5673.2011.02.017</Citation><ArticleIdList><ArticleId IdType="doi">10.3969/j.issn.1005-5673.2011.02.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew OM, Sutter RW, De Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. (2005) 59:587&#x2013;635. 10.1146/annurev.micro.58.030603.123625</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.micro.58.030603.123625</ArticleId><ArticleId IdType="pubmed">16153180</ArticleId></ArticleIdList></Reference><Reference><Citation>Polio Global Eradication Initiative,. Polio Eradication Endgame Strategic Plan. Polio Global Eradication Initiative. Elektrobit/OL  (2013&#x2013;2018). Available online at: http://www.Polioeradication.org/Portals/0/Document/Resources/StrategyWork/Peesp_ES_EN_A4.pdf (accessed May 8, 2013).</Citation></Reference><Reference><Citation>Stanley AP, Walter AO, Paul AO. Vaccine. 5th edition. Singapore: Elsevier Pvt Ltd. (2008).</Citation></Reference><Reference><Citation>WHO . Polio vaccines: WHO position paper, March 2016. WER (2016) 91:145&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">27039410</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . Global eradication of poliomyelitis by the year 2000. WER. (1988) 14:219&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">3242907</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . Expanded program on immunization. Poliomyelitis in 1987, 1988 and 1989-Part. WER. (1991) 66:49&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">2021524</ArticleId></ArticleIdList></Reference><Reference><Citation>Aylward B, Tangermann R. The global polio eradication initiative lessons learned and prospects for success. Vaccine. (2011) 29 (Suppl 14):D80&#x2013;5. 10.1016/j.vaccine.2011.10.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.10.005</ArticleId><ArticleId IdType="pubmed">22486981</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang X, Zhang Y, Xu W, Wen N, Zuo S, Lee LA, et al. . An outbreak of poliomyelitis caused by typeIvaccine-derived poliovirus in China. J Infect Dis. (2006) 194:545&#x2013;51. 10.1086/506359</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/506359</ArticleId><ArticleId IdType="pubmed">16897650</ArticleId></ArticleIdList></Reference><Reference><Citation>Polio Eradication,. WHO Global Action Plan to Minimize Poliovirus Facility-Associated Risk After Type-Specific Eradication of Wild Polioviruses Sequential Cessation of OPV Use. Geneva: World Health Organization  (2014). Available online at: http://www.polioeradication.org/Portals/0/Document/Resources/PostEradication/GAPIII_2014.pdf (accessed July 2015)</Citation></Reference><Reference><Citation>Lane EJ. The world's first inactivated vaccine for the Sabin strain of poliomyelitis was approved for marketing. Eval Anal Drug. (2015) 15:18.</Citation></Reference><Reference><Citation>WHO . Meeting of the strategic advisory group of experts on immunization, April 2016&#x2013; conclusions and recommendations. WER. (2016) 91:265&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">27236869</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao G, Li R, Li C, Sun M, Jiang S, Li Y, et al. . Phase 3 trial of a sabin strain-based inactivated poliovirus vaccine. J Infect Dis. (2016) 214:1728&#x2013;34. 10.1093/infdis/jiw433</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw433</ArticleId><ArticleId IdType="pubmed">27658691</ArticleId></ArticleIdList></Reference><Reference><Citation>*. Qiu J, Yang Y, Huang L, Wang L, Jiang Z, Gong J, et al. . Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: a randomized controlled non-inferiority clinical trial. Hum Vaccin Immunother. (2017) 13:1&#x2013;10. 10.1080/21645515.2017.1288769</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2017.1288769</ArticleId><ArticleId IdType="pmc">PMC5489289</ArticleId><ArticleId IdType="pubmed">28362135</ArticleId></ArticleIdList></Reference><Reference><Citation>*. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press; (1997).</Citation></Reference><Reference><Citation>*. Zhang N, Shi XF, Wu J. The application of incremental cost-effectiveness ratio to health technology assessment. Chin J Health Policy. (2012) 5:64&#x2013;8. 10.3969/j.issn.1674-2982.2012.02.012</Citation><ArticleIdList><ArticleId IdType="doi">10.3969/j.issn.1674-2982.2012.02.012</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>*. Sangrujee N, C&#xe1;ceres VM, Cochi SL. Cost analysis of post-polio certification immunization policies. Bull World Health Organ. (2004) 82:9&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2585890</ArticleId><ArticleId IdType="pubmed">15106295</ArticleId></ArticleIdList></Reference><Reference><Citation>*. Tao LN, Liu JC. Evaluation method of cold chain volume based on vaccine volume and inoculation number. Chin J Vaccine Immun. (2014) 20:454&#x2013;8.</Citation></Reference><Reference><Citation>*WHO . User Guide for WHO Vaccine Volume Calculator [EB/OL]. WHO. Available online at: http://www.who.int/immunization/programmes_systems/supply_chain/resources/tools/en/index4.html</Citation></Reference><Reference><Citation>*World Health Organization . The world health organization (WHO) about the use of oral polio vaccine introduced inactivated polio inactivated opinion. Epidemiol Wkly. Q(2003) 78.</Citation></Reference><Reference><Citation>*. Platt LR, Estivariz CF, Sutter RW. Vaccine-Associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis. (2014) 210 (Suppl. 1):S380&#x2013;9. 10.1093/infdis/jiu184</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu184</ArticleId><ArticleId IdType="pmc">PMC10424844</ArticleId><ArticleId IdType="pubmed">25316859</ArticleId></ArticleIdList></Reference><Reference><Citation>*. Liu Y, Wang J, Liu S, Du J, Wang L, Gu W, et al. . Introduction of inactivated poliovirus vaccine leading into the polio eradication endgame strategic plan; Hangzhou, China, 2010-2014. Vaccine. (2017) 35:1281&#x2013;6. 10.1016/j.vaccine.2017.01.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.01.034</ArticleId><ArticleId IdType="pubmed">28161421</ArticleId></ArticleIdList></Reference><Reference><Citation>*. Ulla KG, Lindsay, Barry D. The cost-effectiveness of alternative polio immunizationpolicies in South Africa. Vaccine. (2006) 24:5670&#x2013;8. 10.1016/j.vaccine.2006.05.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2006.05.032</ArticleId><ArticleId IdType="pubmed">16766096</ArticleId></ArticleIdList></Reference><Reference><Citation>*. Li RP, Xu AQ. Strategic Analysis and Cost Estimation of Using SABin-IPV Instead of OPV in The Late Stage of Poliomyelitis Eradication in China. Jinan: Shandong University; (2007).</Citation></Reference><Reference><Citation>*. Dai F, Zhang RZ. Economic burden of poliomyelitis. Zhonghua Liu Xing Bing Xue Za Zhi. (1996) 17:169&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">9208518</ArticleId></ArticleIdList></Reference><Reference><Citation>*. Cheng XM. In the Field of Medical and Health Care Cost&#x2014;Benefit Analysis. Shanghai: Shanghai Medical University Press; (1994).</Citation></Reference><Reference><Citation>*. Alleman MM, Jorba J, Henderson E, Diop OM, Shaukat S, Traor&#xe9; MA, et al. . Update on vaccine-derived poliovirus outbreaks - worldwide, January 2020-June 2021. MMWR Morb Mortal Wkly Rep. (2021) 70:1691&#x2013;9. 10.15585/mmwr.mm7049a1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7049a1</ArticleId><ArticleId IdType="pmc">PMC8659190</ArticleId><ArticleId IdType="pubmed">34882653</ArticleId></ArticleIdList></Reference><Reference><Citation>*. Zhao H, Ma X, Tang H, Zhang Y, Chen N, Kaisaier W, et al. . Circulation of type 2 vaccine-derived poliovirus in China in 2018-2019. Open Forum Infect Dis. (2021) 8:ofab535. 10.1093/ofid/ofab535</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab535</ArticleId><ArticleId IdType="pmc">PMC8677525</ArticleId><ArticleId IdType="pubmed">34926714</ArticleId></ArticleIdList></Reference><Reference><Citation>*. Zhang Y, Zhu SL, Yan DM, Wang DY, Li XL, Zhu H, et al. . Type I vaccine-derived polioviruses in China from 1995 to 2019. Biosaf Health. (2019) 3:155&#x2013;8. 10.1016/j.bsheal.2019.12.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bsheal.2019.12.002</ArticleId></ArticleIdList></Reference><Reference><Citation>*. Thompson KM, Tebbens RJ. Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation. Expert Rev Vaccines. (2012) 11:449&#x2013;59. 10.1586/erv.11.195</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erv.11.195</ArticleId><ArticleId IdType="pubmed">22551030</ArticleId></ArticleIdList></Reference><Reference><Citation>*. Wen N, Fan CX, Yan DM, Zhu SL, Wang HB, Liu B, et al. . Epidemiological characteristics of vaccine-derived poliovirus and its cases in China from 2001 to 2013. Chin J Vaccine Immun. (2014) 20:210&#x2013;5.</Citation></Reference><Reference><Citation>*WHO . WHO Guide to Generalized Cost-Effectiveness Analysis [EB/OL]. WHO. Available online at: http://www.who.int/choice/publications/p_2003_generalised_cea.PDF</Citation></Reference><Reference><Citation>*. Yang LX. Incremental Cost Study of Inactivated Poliovirus Vaccine into National Immunization Program. Beijing: Chinese Center for Disease Control and Prevention; (2015)</Citation></Reference><Reference><Citation>*. Sartori AM, Vicentine MP, Gryninger LC, So&#xe1;rez PC, Novaes HM. Polio inactivated vaccine costs into routine childhood immunization in Brazil. Rev Saude Publica. (2015) 49:8. 10.1590/S0034-8910.2015049005492</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S0034-8910.2015049005492</ArticleId><ArticleId IdType="pmc">PMC4386566</ArticleId><ArticleId IdType="pubmed">25741645</ArticleId></ArticleIdList></Reference><Reference><Citation>*. Khan MM, Sharma S, Tripathi B, Alvarez FP. Budget impact of polio immunization strategy for India: introduction of one dose of inactivated poliomyelitis vaccine and reductions in supplemental polio immunization. Public Health. (2017) 142:31&#x2013;8. 10.1016/j.puhe.2016.10.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.puhe.2016.10.016</ArticleId><ArticleId IdType="pubmed">28057194</ArticleId></ArticleIdList></Reference><Reference><Citation>*. Domingues CM, de F&#xe1;tima Pereira S, Cunha Marreiros AC, Menezes N, Flannery B. Introduction of sequential inactivated polio vaccine-oral polio vaccine schedule for routine infant immunization in Brazil's national immunization program. J Infect Dis. (2014) 210 (Suppl. S1):S143&#x2013;51. 10.1093/infdis/jit588</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit588</ArticleId><ArticleId IdType="pmc">PMC4758462</ArticleId><ArticleId IdType="pubmed">25316829</ArticleId></ArticleIdList></Reference><Reference><Citation>*. Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Thompson KM. An economic analysis of poliovirus risk management policy options for 2013-2052. BMC Infect Dis. (2015) 15:389. 10.1186/s12879-015-1112-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-015-1112-8</ArticleId><ArticleId IdType="pmc">PMC4582932</ArticleId><ArticleId IdType="pubmed">26404632</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2020;World Health Organization. World schedule as of . WHO  (2013). Available online at: http://www.who.int/immunization/monitoring_surveillance/data/en/ (accessed May 19, 2014).</Citation></Reference><Reference><Citation>&#x2020;. Thompson KM, Duintjer Tebbens RJ. National choices related to inactivated poliovirus vaccine, innovation, and the end game of global polio eradication. Exp Rev Vaccines. (2014) 13:221&#x2013;34. 10.1586/14760584.2014.864563</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2014.864563</ArticleId><ArticleId IdType="pubmed">24308581</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2020;. Tebbens RJD, Pallansch MA, Cochi SL, Wassilak SG, Linkins J, Sutter RW, et al. . Economic analysis of the global polio eradication initiative. Vaccine. (2010) 29:334&#x2013;43. 10.1016/j.vaccine.2010.10.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.10.026</ArticleId><ArticleId IdType="pubmed">21029809</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2020;World Health Organization Department Immunization . Principles and Considerations for Adding a Vaccine to a National Immunization Programme: From Decision to Implementation and Monitoring. Geneva: WHO; (2014).</Citation></Reference><Reference><Citation>&#x2020;. Alvis N, De LHF, Narv&#xe1;ez J. Economic impact of introducing the injectable inactivated polio vaccine in Colombia. Rev Panam Salud Publica. (2010) 27:352&#x2013;9. 10.1590/S1020-49892010000500005</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S1020-49892010000500005</ArticleId><ArticleId IdType="pubmed">20602069</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2020;. Ren J, Maimaiti H, Sun X, Huang Z, Liu J, Yang J, et al. . Cost-Effectiveness of three poliovirus immunization schedules in Shanghai, China. Vaccines. (2021) 9:1062. 10.3390/vaccines9101062</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9101062</ArticleId><ArticleId IdType="pmc">PMC8541293</ArticleId><ArticleId IdType="pubmed">34696170</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2020;. Ivanova OE, Eremeeva TP, Morozova NS. Vaccine-associated paralytic poliomyelitis in the Russian federation in 1998&#x2013;2014. Int J Infect Dis. (2018) 76:64&#x2013;9. 10.1016/j.ijid.2018.08.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2018.08.017</ArticleId><ArticleId IdType="pubmed">30201507</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2020;. Alexander LN, Seward JF, Santibanez TA, Pallansch MA, Kew OM, Prevots DR, et al. . Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA. (2004) 292:1696&#x2013;701. 10.1001/jama.292.14.1696</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.292.14.1696</ArticleId><ArticleId IdType="pubmed">15479934</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2020;. Miller MA, Sutter RW, Strebel PM, Hadler SC. Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule. JAMA. (1996) 276:967&#x2013;71. 10.1001/jama.276.12.967</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.276.12.967</ArticleId><ArticleId IdType="pubmed">8805731</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2020;Circulating Vaccine-Derived Poliovirus (cVDPV) . Available online at: https://polioeradication.org/wp-content/uploads/2020/12/20201118_cVDPV2_Global_Update_EN.pdf (accessed September 21, 2021).</Citation></Reference><Reference><Citation>&#x2020;. Tucker AW, Isaacs D, Burgess M. Cost-effectiveness analysis of changing from live oral poliovirus vaccine to inactivated poliovirus vaccine in Australia. Aust N Z J Public Health. (2001) 25:411&#x2013;6. 10.1111/j.1467-842X.2001.tb00648.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1467-842X.2001.tb00648.x</ArticleId><ArticleId IdType="pubmed">11688618</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2020;. Duintjer TRJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, et al. . Expert review on poliovirus immunity and transmission. Risk Anal. (2013) 33:544&#x2013;605. 10.1111/j.1539-6924.2012.01864.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1539-6924.2012.01864.x</ArticleId><ArticleId IdType="pmc">PMC7896540</ArticleId><ArticleId IdType="pubmed">22804479</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2020;. Anis E, Kopel E, Singer SR, Kaliner E, Moerman L, Moran-Gilad J, et al. . Insidious reintroduction of wild poliovirus into Israel, 2013. Euro Surveill. (2013) 18:20586. 10.2807/1560-7917.ES2013.18.38.20586</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES2013.18.38.20586</ArticleId><ArticleId IdType="pubmed">24084337</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2020;. Kalkowska DA, Duintjer Tebbens RJ, Grotto I, Shulman LM, Anis E, Wassilak SG, et al. . Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. J Infect Dis. (2015) 211:1800&#x2013;12. 10.1093/infdis/jiu674</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu674</ArticleId><ArticleId IdType="pmc">PMC7887763</ArticleId><ArticleId IdType="pubmed">25505296</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2020;. Wahjuhono G, Revolusiana, Widhiastuti D, Sundoro J, Mardani T, Ratih WU, et al. . Switch from oral to inactivated poliovirus vaccine in Yogyakarta Province, Indonesia: summary of coverage, immunity, and environmentalsurveillance. J Infect Dis. (2014) 210 (Suppl 1):S347&#x2013;52. 10.1093/infdis/jiu060</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu060</ArticleId><ArticleId IdType="pubmed">25316854</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2020;. Thompson KM, Duintjer TRJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, et al. . The risks, costs, and benefits of possible future global policies for managing polioviruses. Am J Public Health. (2008) 98:1322&#x2013;30. 10.2105/AJPH.2007.122192</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/AJPH.2007.122192</ArticleId><ArticleId IdType="pmc">PMC2424088</ArticleId><ArticleId IdType="pubmed">18511720</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2020;. Huang ZY, Hu JY, Sun XD, Yang JP. Analysis of poliomyelitis eradication and recommendations for immunization strategies. J Microbes Infect. (2020) 15:337&#x2013;44.</Citation></Reference><Reference><Citation>&#x2020;WHO . Polio vaccines: WHO position paper, March 2016&#x2014;recommendations. Vaccine. (2017) 35:1197&#x2013;9. 10.1016/j.vaccine.2016.11.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.11.017</ArticleId><ArticleId IdType="pubmed">27894720</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2020;. Nasir UN, Bandyopadhyay AS, Montagnani F, Akite JE, Mungu EB, Uche IV, et al. . Polio elimination in Nigeria: a review. Hum. Vaccines Immunother. (2015) 12:658&#x2013;63. 10.1080/21645515.2015.1088617</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1088617</ArticleId><ArticleId IdType="pmc">PMC4964709</ArticleId><ArticleId IdType="pubmed">26383769</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x2020;. Thompson KM, Duintjer Tebbens RJ. Eradication versus control for poliomyelitis: an economic analysis. Lancet. (2007) 369:1363&#x2013;71. 10.1016/S0140-6736(07)60532-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(07)60532-7</ArticleId><ArticleId IdType="pubmed">17448822</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>